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Abstract
Background: Major depression is a serious mood disorder affecting millions of adults and children worldwide.
While the etiopathology of depression remains obscure, antidepressant medications increase synaptic levels of
monoamine neurotransmitters in brain regions associated with the disease. Monoamine transmitters activate
multiple signaling cascades some of which have been investigated as potential mediators of depression or
antidepressant drug action. However, the diacylglycerol arm of phosphoinositide signaling cascades has not been
systematically investigated, even though downstream targets of this cascade have been implicated in depression.
With the ultimate goal of uncovering the primary postsynaptic actions that may initiate cellular antidepressive
signaling, we have examined the antidepressant-induced production of CDP-diacylglycerol which is both a product
of diacylglycerol phosphorylation and a precursor for the synthesis of physiologically critical glycerophospholipids
such as the phosphatidylinositides. For this, drug effects on [3H]cytidine-labeled CDP-diacylglycerol and
[3H]inositol-labeled phosphatidylinositides were measured in response to the tricyclics desipramine and
imipramine, the selective serotonin reuptake inhibitors fluoxetine and paroxetine, the atypical antidepressants
maprotiline and nomifensine, and several monoamine oxidase inhibitors.
Results: Multiple compounds from each antidepressant category significantly stimulated [3H]CDP-diacylglycerol
accumulation in cerebrocortical, hippocampal, and striatal tissues, and also enhanced the resynthesis of inositol
phospholipids. Conversely, various antipsychotics, anxiolytics, and non-antidepressant psychotropic agents failed
to significantly induce CDP-diacylglycerol or phosphoinositide synthesis. Drug-induced CDP-diacylglycerol
accumulation was independent of lithium and only partially dependent on phosphoinositide hydrolysis, thus
indicating that antidepressants can mobilize CDP-diacylglycerol from additional pools lying outside of the inositol
cycle. Further, unlike direct serotonergic, muscarinic, or α-adrenergic agonists that elicited comparable or lower
effects on CDP-diacylglycerol versus inositol phosphates, the antidepressants dose-dependently induced
significantly greater accumulations of CDP-diacylglycerol.
Conclusion: Chemically divergent antidepressant agents commonly and significantly enhanced the accumulation
of CDP-diacylglycerol. The latter is not only a derived product of phosphoinositide hydrolysis but is also a crucial
intermediate in the biosynthesis of several signaling substrates. Hence, altered CDP-diacylglycerol signaling might
be implicated in the pathophysiology of depression or the mechanism of action of diverse antidepressant
medications.
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Background
Major depression is an increasingly prevalent mood disor-
der that afflicts millions of people worldwide [1-3]. While
a number of medications is available for managing the
disease symptoms, the mechanism of action of current
antidepressants is not well understood [4,5]. It is known,
however, that antidepressant medications generally
increase the synaptic levels of the monoamine neurotrans-
mitters serotonin, norepinephrine, and/or dopamine in
discrete brain regions [6,7]. The monoamines are then
thought to activate their cognate postsynaptic receptors
and modulate the activities of downstream signaling cas-
cades to produce the antidepressive effect [5,8-10].
Monoamine receptors coupled to diverse signaling cas-
cades, including those mediated through adenylyl cyclase,
phospholipases, and MAP Kinases [11-14]. Aspects of
each signaling system have been investigated as potential
downstream targets of antidepressive mechanisms with
multiple and sometimes divergent findings [8,15,16]. As
examples, acute or chronic treatment with various antide-
pressant compounds can lead to changes in basal or drug-
induced activities of brain adenylyl cyclase [17-20], phos-
pholipase A2 [21], CREB [22,23], phosphoinositide-spe-
cific phospholipase C (PLC) [15,24,25], inositol
phosphates (IPs) [26-29], phosphatidylinositides (PI)
[29,30], protein kinase C (PKC) [31-33], extracellular sig-
nal regulated kinase [16,34], ion channels [35,36], neuro-
trophins [37-39], and various neuropeptides [40-42].
Antidepressants can also enhance neurogenesis [43-46],
modulate neuronal excitability [47-49], and alter the gene
expression of various signaling components including
neurotransmitter transporters, receptors, transducers, and
effectors [50-53]. While these observations suggest that
changes in postsynaptic signaling cascades may constitute
an integral component in the mechanisms that underlie
depression or its treatment with antidepressant medica-
tions, no signaling cascade has been identified that ade-
quately explains the behavioral and clinical data.
The PI-related observations in particular have been cor-
roborated by clinical studies showing that depressed per-
sons may have reduced cortical levels of the PI precursor
myo-inositol [54,55]. Moreover, oral ingestion of bolus
doses of myo-inositol could elicit antidepressive responses
in rodents [56,57], and enhance the recovery of clinically
depressed patients [58]. Consistent with these findings,
chronic administration of antidepressant agents has been
associated with increased levels of the PIs in human plate-
lets [29,30]. These observations suggest that alterations in
the PI signaling pathway may be implicated in the patho-
physiology of depression and/or the mode of action of
antidepressant agents [5,25,59,60].
Several past studies examined IP signaling, but not the sta-
tus of diacylglycerol (DG) production or signaling, as a
potential target of disease pathology or pharmacological
treatment with antidepressants [31-33]. Diacylglycerol
signaling is important because this lipid is the endog-
enous regulator of PKC activity, and the latter is one of the
indices shown to be altered in depressed persons [31-
33,61]. Moreover, PLC-stimulating receptors show differ-
ences in their capacity to generate diacylglycerol (relative
to IP) from phospholipid hydrolysis [62,63]. Therefore, to
the extent that PI signaling or PKC activity may be
involved in antidepressant drug action, it should be
important to clarify the specific effects of the agents on
diacylglycerol production as a potential basis for their
therapeutic efficacy. Following our previously reported
preliminary observations [64], we have now examined
antidepressant drug effects on cellular diacylglycerol pro-
duction and metabolism, including the resynthesis of the
PI substrates. The results show that antidepressants
belonging to diverse chemical and pharmacological
classes acutely increase the formation of CDP-diacylglyc-
erol (CDP-DG), a metabolic derivative of diacylglycerol,
and that this effect does translate to enhanced resynthesis
of the PIs. The latter are physiologically critical not only as
substrates for PLC signaling but also as mediators in the
phosphatidylinositol-3-kinase (PI3K)/Akt signaling cas-
cades. It is conceivable, therefore, that an acute molecular
action of antidepressant agents that conserves or supple-
ments cellular PIs could ultimately contribute to the ther-
apeutic mechanism of these medications in depression.
Results
Chemically diverse antidepressant agents increase CDP-
diacylglycerol production
Diacylglycerol released from phospholipid breakdown is
normally rapidly phosphorylated to produce phospha-
tidic acid. In the presence of [3H]cytidine-labeled CTP,
however, the phosphatidic acid is converted to radiola-
beled CDP-DG, which can be extracted and separated
away from other labeled metabolites and subsequently
quantified. In the present study, rat brain cerebrocortical,
hippocampal, and striatal slices prelabeled with [3H]cyti-
dine were incubated with various concentrations of
selected antidepressant agents in the presence of LiCl, and
the yield of CDP-diacylglycerol analyzed. Data for each
drug were separately analyzed before they were normal-
ized and collated together for graphical presentation as
shown. The classical antidepressants imipramine and
desipramine, the selective serotonin reuptake inhibitors
fluoxetine and paroxetine, and the atypical agents mapro-
tiline and nomifensine, each significantly and dose-
dependently enhanced the accumulation of [3H]CDP-DG
in rat hippocampal, prefrontal cortical, and striatal slices
(Figure 1). While concentrations ranging from 0.1 to 1000
μM were tested, only those concentrations lying betweenBMC Neuroscience 2008, 9:12 http://www.biomedcentral.com/1471-2202/9/12
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Effects of classic antidepressants on [3H]CDP-diacylglycerol accumulation Figure 1
Effects of classic antidepressants on [3H]CDP-diacylglycerol accumulation. Tissue slices prepared from indicated 
brain regions were prelabeled with [3H]cytidine and incubated with various concentrations of either imipramine (IMI), 
desipramine (DES), fluoxetine (FLU), paroxetine (PAR), maprotiline (MAP), or nomifensine (NOM). After 90 min, tissue con-
tents of [3H]CDP-diacylglycerol were assayed. Each bar is the mean ± SEM (N = 9). Each drug stimulated significant concentra-
tion-dependent accumulations of CDP-diacylglycerol (ANOVA, p < 0.001 for each drug). Based on posthoc Dunnett tests, all 
agents induced statistically significant CDP-diacylglycerol responses at the 3 or 10 μM concentrations, except for paroxetine in 
the hippocampus and imipramine in the striatum where the drug effects were not significant until the 30 μM and higher con-
centrations.BMC Neuroscience 2008, 9:12 http://www.biomedcentral.com/1471-2202/9/12
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the minimal that gave statistically significant effects for
any agent (1–3 μM) and the maximally effective concen-
trations (100 – 500 μM) are shown. Statistically signifi-
cant effects were obtained at concentrations as low as
3–10 μM in the hippocampus or prefrontal cortex, while
maximal effects were achieved at the 100 μM concentra-
tion of fluoxetine or 300 μM concentrations of most other
agents. For all agents, test concentrations greater than 300
μM resulted in CDP-DG effects that were either statisti-
cally similar to, or significantly lower than, the effects
observed at 100 μM for fluoxetine or 300 μM for the other
agents. This reduction in response with increasing concen-
tration after attaining maximal responses was more appar-
ent with the SSRIs, fluoxetine and paroxetine, than with
the tricyclic agents.
Among the brain regions, the hippocampus appeared to
be more sensitive (greater response magnitudes at lower
concentrations), whereas the striatum gave slightly more
robust (maximally attained) effects. The drug responses
were statistically dose-dependent for all effective agents in
each tissue, but there were noticeable differences in
potency or efficacy among the compounds as shown in
the data. Thus, diverse antidepressant agents can acutely
induce CDP-DG synthesis in depression-relevant regions
of the rat brain.
Antidepressant-induced CDP-diacylglycerol formation 
translates into increased PI synthesis
To test if the antidepressant-enhanced CDP-DG translates
into increased synthesis of the PIs, brain slice preparations
were labeled with [3H] inositol and incubated in the pres-
ence of various antidepressant agents. Results of the sub-
sequent uptake and conversion of [3H] inositol into
inositol phospholipids are shown in Figure 2. Imi-
pramine, desipramine, fluoxetine, paroxetine, and
maprotiline each significantly increased [3H]inositol labe-
ling of PIs in the tested brain regions (Figure 2). Thus, the
increased mobilization or recapture of CDP-DG by the
antidepressant agents translates into increased regenera-
tion of PI signaling substrates.
Effects of monoamine oxidase inhibiting agents CDP-
diacylglycerol formation and PI synthesis
Similar to the effects exhibited by the classical antidepres-
sant agents, the monoamine oxidase inhibitors (MAOIs),
phenelzine and hydralazine, produced robust effects on
CDP-DG accumulation in frontal cortex slices (Figure 3),
while tranylcypromine had statistically significant but
rather modest effects (data not shown). While the effects
of phenelzine achieved significance at 1 μM (Dunnett's, p
< 0.01), those of hydralazine became significant at the 10
μM and higher concentrations. Conversely, no significant
effects were observed with several other tested MAOIs,
namely, pargyline, selegiline, quinacrine, or clorgyline
(Table 1).
MAOIs that were effective in inducing CDP-DG produc-
tion also showed enhanced effects on PI resynthesis (Fig-
ure 3), whereas other MAOIs that were ineffective on
CDP-DG were equally ineffective in increasing PI resyn-
thesis (data not shown). The MAOI data (Figure 3) also
depict the significantly greater relative accumulation of
PIs compared to the accumulation of CDP-DG, implying
the conversion of CDP-DG to PI may be a dynamic or
cumulative process.
We also tested a range of other psychotropic compounds
in order to estimate the extent to which the CDP-DG
response may characterize compounds with antidepres-
sive activity. Neither the antipsychotic agents sulpiride,
chlorpromazine and haloperidol, nor various other psy-
chotropic compounds induced any significant effects on
CDP-DG production (Table 1).
Antidepressant Agents Generally Enhance Inositol 
Phosphate Accumulation
To test if resynthesized PIs might contribute to enhanced
IP accumulation, agents tested for effects on CDP-DG
were also tested in a standard IP assay. Across a concentra-
tion range of 3–300 μM, imipramine, desipramine, fluox-
etine, paroxetine, and maprotiline significantly and dose-
dependently stimulated the accumulation of IPs in each
brain region (Figure 4). Significant drug effects were gen-
erally evident at concentrations of 3–10 μM, while maxi-
mal effects were observed at 100–300 μM. With
imipramine tested in the hippocampus and striatum as
the only possible exceptions, test concentrations greater
than 300 μM resulted in IP effects that were either statisti-
cally similar to, or significantly lower than, the effects
observed at the corresponding 300 μM concentration. In
general, drug concentrations greater than 300–500 μM
were associated with IP levels that were significantly lower
than effects at 100–300 μM concentrations, possibly
reflecting toxicity from excessive stimulation.
Antidepressant-induced CDP-diacylglycerol formation 
partially depends on PI hydrolysis
Phosphoinositide hydrolysis is a major source, but not the
only possible source, of diacylglycerol in the cell. To esti-
mate the extent to which antidepressant-enhanced CDP-
DG may derive from PI breakdown, we blocked PI hydrol-
ysis and then measured the consequent effects on the abil-
ity of antidepressant agents to induce CDP-DG
accumulation. First, we tested the effects of the general PI
metabolism inhibitor, neomycin, against the maximally
effective concentrations of the selected antidepressant
agents. Neomycin concentration-dependently blocked
the effects of imipramine, desipramine, fluoxetine, parox-BMC Neuroscience 2008, 9:12 http://www.biomedcentral.com/1471-2202/9/12
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Effects of various classic antidepressants on [3H]phosphatidylinositide synthesis Figure 2
Effects of various classic antidepressants on [3H]phosphatidylinositide synthesis. Tissue slices prepared from indi-
cated brain regions and prelabeled with [3H]inositol were incubated with various concentrations of either imipramine (IMI), 
desipramine (DES), fluoxetine (FLU), paroxetine (PAR), or maprotiline (MAP). After 90 min, [3H]inositol phospholipids were 
extracted and assayed as a total pool of extractable phosphatidylinositides. Each bar is the mean ± SEM (N = 9). Each drug 
stimulated significant and concentration-dependent increases in [3H]inositol phospholipid synthesis (ANOVA, p < 0.001 for 
each drug). From the subsequent posthoc Dunnett tests, all agents induced statistically significant CDP-diacylglycerol responses 
at the 3 or 10 μM and higher concentrations.BMC Neuroscience 2008, 9:12 http://www.biomedcentral.com/1471-2202/9/12
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etine, maprotiline, or nomifensine on CDP-DG produc-
tion (Figure 5A), PI resynthesis (Figure 5B) or IP
accumulation (data not shown) in hippocampal or pre-
frontal cortical brain slices. Increasing concentrations of
neomycin produced complete blockade of both CDP-DG
and PI responses. We next tested the effects of the selective
PLC inhibitor, U73122, on the drug responses. As shown
in Figure 6, U73122 by itself did not significantly alter
basal CDP-DG production (Figure 6A) or IP accumulation
(Figure 6B), although a slight increase in IP was consist-
ently noted. At concentrations ranging from 0.1 to 10 μM,
U73122 significantly reduced, but was unable to com-
pletely block, antidepressant drug effects on CDP-DG pro-
duction. Conversely, the PLC inhibitor completely
blocked IP stimulation by 100 μM fluoxetine or 300 μM
concentrations of imipramine, paroxetine, maprotiline,
or nomifensine in hippocampal or cortical slices. To vali-
date the effects of U73122, we also tested the compound
against the action of SKF38393, a D1 receptor agonist that
is known to induce PI hydrolysis in these brain tissues
[14,65]. SKF38393-induced IP accumulation was blocked
by U73122 with similar efficacies to the inhibition of the
antidepressant responses (Figure 6B). Moreover, U73123,
an analog of U73122 that is ineffective in blocking PLC
activity, was without effect on any of the CDP-DG or IP
responses (data not shown). The effects of the SSRIs fluox-
etine and paroxetine were more sensitive to inhibition by
U73122 than the effects of the tricyclic agents.
Lithium is not required for antidepressant drug effects on 
CDP-diacylglycerol
Our initial experiments were designed to compare antide-
pressant drug effects on the IP and diacylglycerol arms of
the inositol cycle. Thus, it was necessary to include LiCl in
all test incubations, seeing Li+ is needed to block inositol
monophosphatase and thereby enable the accumulation
of released IPs to measurable levels. But, is the presence of
Li+ necessary to demonstrate antidepressant drug effects
on CDP-DG? To answer this question we performed addi-
tional experiments in which selected antidepressant
agents were tested for effects on CDP-DG in the absence
Table 1: Psychotropic agents lacking effects on CDP-
diacylglycerol accumulation in rat cerebrocortical slices. Agents 
were tested at multiple concentrations ranging from 0.1–300 μM. 
Data from up to three separate runs were normalized and 
pooled for analysis by One-Way ANOVA. None of these 
compounds showed significant or concentration-related effects 
on CDP-diacylglycerol.
Antipsychotics MAOIs Anticonvulsants/Anxiolytics/Others
Chlorpromazine Hydroxylamine Benztropine Phenylephrine
Haloperidol Selegiline Phenytoin Phenobarbital
Sulpiride Pargyline Diazepam Chlordiazepoxide
Flupenthixol Quinacrine Nitrazepam
Effects of the monoamine oxidase inhibitors on [3H]CDP-dia- cylglycerol accumulation and phosphatidylinositide synthesis Figure 3
Effects of the monoamine oxidase inhibitors on 
[3H]CDP-diacylglycerol accumulation and phosphati-
dylinositide synthesis. Cortical slices were tested with 
indicated concentrations of phenelzine or hydralazine. CDP-
diacylglycerol (CDP-DG) levels were analyzed as outlined 
under Figure 1, while phosphatidylinositide (PI) synthesis was 
measured as the total pool of extractable [3H]inositol-labeled 
phospholipids as in Figure 2. Each point is the mean ± SEM 
(N = 9). Each drug stimulated significant concentration-
dependent accumulations of CDP-diacylglycerol (ANOVA, p 
< 0.001 for each drug) and phosphatidylinositide synthesis 
(ANOVA, p < 0.001 for each drug). Note that if individually 
compared to the corresponding control measure, each of the 
tested concentrations from 0.1 – 300 μM gave statistically 
significant effects on CDP-DG and PIs. Note also the greater 
relative accumulation of PIs compared to the accumulation of 
CDP-DG.BMC Neuroscience 2008, 9:12 http://www.biomedcentral.com/1471-2202/9/12
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Effects of diverse antidepressants on [3H]inositol phosphate accumulation Figure 4
Effects of diverse antidepressants on [3H]inositol phosphate accumulation. Experiments were conducted as out-
lined in the legend to Figure 2, except that tissue contents of [3H]inositol phosphates were assayed by Dowex anion exchange 
chromatography as detailed in Methods. Each bar is the mean ± SEM (N = 9). Each antidepressant agent stimulated significant 
concentration-dependent accumulations of inositol phosphate (ANOVA, p < 0.001 for each drug).BMC Neuroscience 2008, 9:12 http://www.biomedcentral.com/1471-2202/9/12
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or presence of 5 mM LiCl. As shown in Figure 7, LiCl did
not significantly enhance or inhibit antidepressant drug-
induced CDP-DG production, implying that the presence
of Li+  is not necessary to demonstrate the enhancing
effects of antidepressant agents on CDP-DG production.
Antidepressants elicit greater stimulation of CDP-
diacylglycerol production than IP formation
To determine if antidepressant agents exert differential
effects on CDP-DG production compared to PI hydrolysis,
we examined the ratios of CDP-DG production relative to
the IPs (CDP-DG/IP ratio) in corresponding treatment
conditions. The ratios were calculated from the data in
Inhibition of antidepressant-induced [3H]CDP-diacylglycerol production and phosphoinositide synthesis by neomycin Figure 5
Inhibition of antidepressant-induced [3H]CDP-diacylglycerol production and phosphoinositide synthesis by 
neomycin. Slices of rat prefrontal cortex or hippocampus prepared from the same rats were pre-labeled in parallel with 
[3H]cytidine or [3H]inositol and incubated with indicated concentrations of neomycin, followed by addition of 100 μM fluoxet-
ine (FLU) or 300 μM imipramine (IMI), desipramine (DES), paroxetine (PAR), maprotiline (MAP), or nomifensine (NOM). 
Accumulated [3H]CDP-diacylglycerol (A) or [3H]phosphoinositides (B) were measured after 90 min. While only the hippoc-
ampus data are shown for CDP-diacylglycerol and the cortical data for phosphatidylinositides, each analyte was assessed in 
each brain region with similar results. Each bar is the mean ± SEM (n = 6). Neomycin significantly and concentration-depend-
ently inhibited drug-induced [3H]CDP-diacylglycerol production and [3H]inositol phospholipid synthesis (ANOVA, p < 0.01 for 
each drug). The effects of neomycin alone on CDP-diacylglycerol were not significant, whereas it exerted a slight but significant 
increase at the 0.3 mM concentration (Dunett's, p < 0.01) and decrease at the 3 mM concentration (Dunnett, p < 0.01) in 
[3H]phosphatidylinositide levels. #p < 0.05; *p < 0.05, compared to respective effects of antidepressant alone by Dunnett test.BMC Neuroscience 2008, 9:12 http://www.biomedcentral.com/1471-2202/9/12
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Figures 1, 2, 3, 4 and the results are shown in Figure 8.
With each antidepressant agent, the CDP-DG/IP ratios
increased significantly with increasing drug concentra-
tions. This was true for different classes of drugs, including
the MAOIs phenelzine and hydralazine.
Monoamine receptor agonists exert divergent effects on 
CDP-diacylglycerol
In attempts to determine which, if any, of the endogenous
monoaminergic systems may show similar profiles of
CDP-DG/IP effects, additional experiments were con-
ducted with agonists that act directly at PLC-coupled
monoaminergic receptors: α-methylserotonin (5HT2 sero-
tonergic), carbachol (muscarinic cholinergic), SKF38393
Effects of the PLC inhibitor U73122 on antidepressant-mediated CDP-diacylglycerol production and inositol phosphate accu- mulation Figure 6
Effects of the PLC inhibitor U73122 on antidepressant-mediated CDP-diacylglycerol production and inositol 
phosphate accumulation. Cerebrocortical or hippocampal slices labeled with either [3H]inositol or [3H]cytidine were incu-
bated in parallel with buffer alone or the indicated concentrations of U73122, followed by addition of 100 μM fluoxetine (FLU) 
or 300 μM imipramine (IMI), paroxetine (PAR), maprotiline (MAP), nomifensine (NOM), or SKF38393 (SKF) as indicated. 
Accumulated [3H]CDP-diacylglycerol (A) or [3H]inositol phosphates (B) were determined after 90 min. While only the hip-
pocampus data are shown for inositol phosphates and the cortical data for CDP-diacylglycerol, each analyte was assessed in 
each brain region with similar results. Each bar is the mean ± SEM (n = 6). U73122 completely blocked [3H]inositol phosphate 
accumulation stimulated by either antidepressant agent (ANOVA, p < 0.001). Conversely, U73122 only partially reduced anti-
depressant drug-induced [3H]CDP-diacylglycerol production. The phospholipase C inhibitor by itself showed slight but signifi-
cant effects on either analyte. *p < 0.01 compared to effects of antidepressant alone (Dunnett test).BMC Neuroscience 2008, 9:12 http://www.biomedcentral.com/1471-2202/9/12
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(D1-like dopaminergic), and phenylephrine (alpha-
adrenergic). Corresponding CDP-DG ratios were calcu-
lated as for the antidepressant agents. As shown, α-meth-
ylserotonin, carbachol, phenylephrine (Figure 9) or
SKF38393 (Figure 10) significantly increased IP accumu-
lation and CDP-DG production in frontal cortex or hip-
pocampal tissues. Carbachol failed to increase PI
synthesis, SKF38393 significantly enhanced PI synthesis,
while the other two agents had significant but relatively
small effects on PI. The ratios of CDP-DG production rel-
ative to IP accumulation are shown in the corresponding
right panels of Figure 9 and Figure 10. With both carba-
chol and phenylephrine, there was a dramatic decrease in
the CDP-DG/IP ratio. While the ratio did not decrease as
much for α-methylserotonin, there was no concentration-
related increase either. Conversely, SKF38393 increased
CDP-DG/IP ratios significantly and in a manner similar to
the antidepressants (Figure 10). Indeed, even the ratios of
CDP-DG relative to PIs or the combination of both inosi-
tol derivatives (CDP-DG/IP&PI) were significantly
enhanced. Thus, agonists at the direct PLC-coupled
monoamine receptors showed parallel and corresponding
changes between CDP-DG and the inositides, except for
the dopamine agonist which, like the antidepressants,
induced proportionately greater production of CDP-DG
relative to inositide derivatives.
Discussion
Various experimental approaches have been used in the
past to demonstrate positive effects of select antidepres-
sant agents on the IP arm of PI signaling cascades
[15,27,30,66]. The present data demonstrate for the first
time that antidepressant agents could increase by several-
fold the production of CDP-diacylglycerol, a crucial sign-
aling intermediate that is both a derivative of diacylglyc-
erol and a precursor for the biosynthesis of PIs. This effect
appeared to be common across agents from diverse chem-
ical and pharmacological classes, seeing it was obtained
with the tricyclics imipramine and desipramine, the SSRIs
fluoxetine and paroxetine, the atypicals maprotiline and
nomifensine, and the MAO inhibitors phenelzine and
hydralazine. Thus, the findings could point to a mecha-
nism (enhanced phospholipid biosynthesis) and media-
tor (CDP-diacylglycerol) for the biochemical and possibly
clinical effects that may be common across diverse classes
of antidepressants.
Earlier studies observed that several antidepressants
enhanced [3H]IP accumulation and [3H]PI labeling in rat
cortical slices [27,29]. The mechanism of this response
was confounding, seeing other studies that directly
assayed phospholipase C activity suggested that the drugs
could stimulate or inhibit PLC-mediated PI hydrolysis
[15,24]. In the present study, the antidepressants were
equally effective in enhancing CDP-DG in the presence or
absence of LiCl, whereas the presence of Li+ was necessary
to demonstrate the effects of the drugs on IP accumula-
tion. This implies that the compounds do not inhibit IP
breakdown (otherwise they would have substituted for
Li+), and that their effects on IP accumulation is probably
secondary and passive to the enhanced production of
upstream CDP-DG and PI substrates.
Numerous agents acting at diverse receptor systems can
enhance PI metabolism, but few such pure receptor ago-
nists are known to exhibit an antidepressive effect in
humans or animals [67]. How then might an effect of
antidepressant agents on CDP-DG and PI synthesis be
associated with the antidepressive efficacy of the com-
pounds? An attempt to address this question led to com-
parisons of the ratio data between the antidepressants as a
group and agonists at alpha-adrenergic, 5HT2 serotoner-
gic, and dopaminergic receptors (which are implicated in
depression) as well as the muscarinic cholinergic receptor
that is not known to contribute to the actions of antide-
pressant agents. While all these receptors are coupled to PI
hydrolysis, only some 5HT2 agonists and SKF38393 have
Effects of LiCl on antidepressant-induced [3H]CDP-diacylg- lycerol production Figure 7
Effects of LiCl on antidepressant-induced [3H]CDP-
diacylglycerol production. Slices of prefrontal cortical or 
hippocampal tissues were labeled with [3H]cytidine and incu-
bated in the presence or absence of 5 mM LiCl. Indicated 
concentrations of fluoxetine or imipramine were added, and 
after 60 min accumulated [3H]CDP-diacylglycerol was meas-
ured. While the frontal cortex data are shown, similar obser-
vations were made in the hippocampus. Each bar is the mean 
± SEM (n = 6). The presence of LiCl did not significantly alter 
the stimulatory effects of fluoxetine or imipramine on 
[3H]DCP- diacylglycerol accumulation (ANOVA, p > 0.05).BMC Neuroscience 2008, 9:12 http://www.biomedcentral.com/1471-2202/9/12
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been shown to elicit antidepressive effects in rodent mod-
els [67-69]. The ratio of CDP-DG to IP components for
phenylephrine and carbachol decreased, for α-methylse-
rotonin remained unchanged, and for SKF38393
increased, with increasing concentrations of agonist. For
the antidepressant agents, the ratios were not only signif-
icantly elevated, but actually increased in a concentration-
dependent fashion. This was true of all classes of antide-
pressants examined, including the effective members
among the MAO inhibitors. The similarity between the
effects of SKF38393 and the antidepressants may underlie
the behavioral antidepressant efficacy of the compound as
previously demonstrated in the rodent model [69].
Hence, to the extent that CDP-DG production might be
relevant to depression or the mechanism of antidepres-
sant drug action, an antidepressive agent should not
merely increase PI hydrolysis, but the CDP-DG produced
must exceed and probably precede the production of PI
messengers.
It was noteworthy that even the SSRIs produced signifi-
cant increases in each CDP-DG ratio, whereas the direct
5HT2 agonist α-methylserotonin did not. If the biological
actions of the SSRIs were limited to the actions of the
Ratios of antidepressant-induced CDP-diacylglycerol versus inositol phosphates Figure 8
Ratios of antidepressant-induced CDP-diacylglycerol versus inositol phosphates. The data in Figures 1-4 were recal-
culated by dividing the CDP- diacylglycerol effects of each concentration of each antidepressant agent by the corresponding 
effects of the agent on inositol phosphate accumulation to yield the CDP- diacylglycerol/inositol phosphate (CDP-DG/IP) ratios 
shown. To facilitate merging of data from multiple experiments, these values were converted to percentages relative to the 
ratio values in the respective control samples and then averaged to give the mean ± SEM shown for the classic agents (A), 
phenelzine (B), and hydralazine (C). Data for the hippocampus are shown, but similar observations were made in the cortical 
tissues. Data for each agent were analyzed by One-way ANOVA followed by posthoc Dunnett tests. #p < 0.05; *p < 0.01; com-
pared to the respective control (zero drug concentration).BMC Neuroscience 2008, 9:12 http://www.biomedcentral.com/1471-2202/9/12
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Effects of α-methylserotonin, carbachol, and phenylephrine on CDP-diacylglycerol production, inositol phosphate accumulation  and phosphatidylinositide synthesis Figure 9
Effects of α-methylserotonin, carbachol, and phenylephrine on CDP-diacylglycerol production, inositol phos-
phate accumulation and phosphatidylinositide synthesis. Slices of prefrontal cortical or hippocampal tissues were pre-
labeled with [3H]cytidine or [3H]inositol in parallel, and then incubated in the presence of 5 mM LiCl. Indicated concentrations 
of the agonists were added for 90 min, followed by assay of the levels of [3H]CDP- diacylglycerol, [3H]inositol phosphates, and 
[3H]phosphoinositides. Calculated ratios of CDP- diacylglycerol over inositol phosphates (CDP-DG/IP ratios) are shown in the 
rightmost panel relative to the scale on the right y-axis. Each bar is the mean ± SEM (n = 15 for α-methylserotonin, 12 for car-
bachol, 9 for phenylephrine). Data were separately analyzed by One-way ANOVA for each receptor agonist. *p < 0.01, Dun-
nett test compared to the respective control (zero drug concentration).BMC Neuroscience 2008, 9:12 http://www.biomedcentral.com/1471-2202/9/12
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Effects of SKF38393 on CDP-diacylglycerol production, inositol phosphate accumulation and phosphatidylinositide synthesis Figure 10
Effects of SKF38393 on CDP-diacylglycerol production, inositol phosphate accumulation and phosphatidyli-
nositide synthesis. Prefrontal cortical slices pre-labeled with [3H]cytidine or [3H]inositol in parallel were incubated with indi-
cated concentrations of SKF38393 in the presence of 5 mM LiCl for 90 min, followed by assay of [3H]CDP-diacylglycerol (A), 
[3H]phosphoinositides (B) and [3H]inositol phosphates (C). Calculated ratios of CDP-diacylglycerol over inositol phosphates 
(CDP-DG/IP ratio), phosphatidylinositides (CDP-DG/PI ratio), or the sum of the inositol phosphates and phosphatidyli-
nositides (CDP-DG/IPPI ratio) are shown in the right panel (D-E, respectively). Each bar is the mean ± SEM (n = 12). Data 
were analyzed by One-way ANOVA and posthoc Dunnett tests. #p < 0.05; *p < 0.01, compared to the respective control by 
Dunnett test.BMC Neuroscience 2008, 9:12 http://www.biomedcentral.com/1471-2202/9/12
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drugs to enhance synaptic serotonin levels, then one
would expect direct serotonin receptor stimulation to
elicit similar effects. This disparity should suggest that
facilitation of synaptic serotonin levels may not be the
sole or sufficient mechanism of action of the SSRIs.
Rather, antidepressant-enhanced synaptic serotonin may
work in concert with antidepressant-facilitated neurolipid
biosynthesis to achieve the type and level of downstream
signaling responses that may contribute to the antidepres-
sive effect.
Although CDP-DG production induced by the antidepres-
sants may be derived from phosphoinositide breakdown,
it is not impossible that the CDP-DG pool may be gener-
ated from additional endogenous sources. In an initial
attempt to address this, we observed that antidepressant-
mediated accumulation of [3H]CDP-DG was completely
blocked by the non-specific phosphoinositide inhibitor,
neomycin, in prefrontal or hippocampal tissues. Con-
versely, the selective PLC inhibitor U73122 could only
partially decrease CDP-DG production, while it com-
pletely blocked the release of IPs. These results suggest
that, while the integrity of the phosphoinositide pool is
essential to the full effect of antidepressant agents on
CDP-DG (based on the neomycin data), the PLC-accessi-
ble pool of phosphoinositides may not be the only source
of antidepressant-mediated CDP-DG production (based
on the U73122 data). It is known that neural (and other)
cells maintain multiple pools of phosphoinositides not
all of which may be accessible to PLC-mediated cycling.
The possibility that the antidepressants could mobilize
these additional reserves of PI substrates, particularly fol-
lowing acute or chronic metabolic depletion of the sub-
strates, should be an interesting subject for future
investigations.
A critical question that was also attempted relates to the
extent to which the CDP-DG response may be specific to
antidepressant agents versus other psychotropic drugs.
After testing a wide range of compounds, we observed that
neither the antipsychotics chlorpromazine and haloperi-
dol, nor several other psychotropic agents were capable of
inducing the degree of CDP-DG effects observed with the
antidepressant agents. While this suggests that the CDP-
DG effect, particularly the dose-related effect on CDP-DG/
IP ratio, could reflect a characteristic property of antide-
pressant medications, we were equally surprised by the
disparity in efficacy among the MAO inhibitors. The inef-
fective agents included the nonselective MAO A/B inhibi-
tor clorgyline, and the selective MAO-B inhibitors
pargyline and selegiline. At least one of these, clorgyline,
is used clinically for the treatment of depression. Con-
versely, other MAO inhibitors, including phenelzine,
hydralazine and tranylcypromine were significantly effec-
tive in inducing CDP-DG. The chemical or biological
basis for this disparity among the MAOIs is still unclear.
Indeed, considering the relatively marked effects of
phenelzine and hydralazine, it is possible that inhibition
of MAO-mediated monoamine breakdown may not be
the predominant mechanism by which these compounds
modulate CDP-DG signaling.
It remains to be determined how the present in vitro obser-
vations may relate to in vivo drug concentrations or behav-
ioral effects. While all tested antidepressants generally
induced significant CDP-DG or PI effects at concentra-
tions of 1–10 μM (and as low as 0.1–0.3 μM for
phenelzine and hydralazine), the in vivo concentrations
or doses needed to induce comparable effects have not
been determined. Nevertheless, a recent report suggests
that antidepressants may induce in vivo CDP-DG or phos-
phoinositide effects at doses commonly used to elicit anti-
depressant-like behaviors in animal models [70].
Additional studies should help to clarify these questions.
Conclusion
Collectively, the present data raise the speculation that
depression may be associated with decreased turnover or
biological efficacy of phosphoinositide-related signaling
systems, possibly due to depletion of phosphoinositide
substrates. Antidepressants may act by mobilizing CDP-
DG to help replenish or supplement the pool of available
PIs. In addition to PLC-mediated cascades, phosphatidyli-
nositol is a key substrate for the PI3K signaling pathway
[71]. Earlier reports showed that PI3K signaling is relevant
to the induction of neurogenesis or neuronal survival and
plasticity [72,73]. A recent study determined that the
activity of PI3K and its downstream target, Akt, is
decreased in postmortem brain tissues of depressed sui-
cide victims [74]. Extensive interactions or crosstalk exists
among downstream mediators of the PLC and PI3K sys-
tems and other signaling pathways that have been impli-
cated in depression. Thus, it is conceivable that an early
action of antidepressant agents to enhance the mobiliza-
tion of CDP-DG could lead to coordinate effects on mul-
tiple signaling systems, which might then explain the
various molecular, structural, and functional effects of the
drugs. The data, however, do not exclude the possibility
that multiple signaling pathways, including the adenylyl
cyclase pathway, may be involved in depression or the
mechanism of action of antidepressant agents. Nor do the
data directly address the conventional notion that antide-
pressive medications need be administered chronically in
order to elicit a clinical effect. Additional studies also are
required before a model could emerge that might relate
these findings to the various theories of depression or
antidepressant mechanisms. Notwithstanding these
pending questions, the present CDP-DG findings demon-
strate a functional biochemical response that is common
across divergent antidepressant classes, is elicited withinBMC Neuroscience 2008, 9:12 http://www.biomedcentral.com/1471-2202/9/12
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the time frame that the drug is available to the tissues, and
may have a plausible role in the pathology of depression
or the mechanism of action of current antidepressive
agents.
Methods
Animals
Male Sprague-Dawley rats weighing 225–250 g were
obtained from Zivic Laboratories (Zelienople, PA) and
housed in climate-controlled facilities with a 12-h light/
dark cycle for at least 3 days before use. The animals were
caged in groups of three and allowed free access to food
and water. Protocols for the care and use of the experi-
mental animals were approved by the Institutional Ani-
mal Care and Use Committee and conformed to the
National Institutes of Health Guide for the Care and Use
of Laboratory Animals.
Drugs and chemicals
Antidepressant compounds and buffer reagents were pur-
chased from Sigma-Aldrich (St. Louis, MO). SKF38393
was a gift from the NIMH Chemical Synthesis Program
(NIMH, Bethesda, US). Nomifensine was first dissolved in
0.2% tartaric acid and SKF38393 in distilled water before
either drug was diluted to use concentrations in assay
buffer. Other drugs were prepared fresh in HEPES bicarbo-
nate assay buffer (HBB) [65]. Each experiment was per-
formed on multiple occasions using fresh preparations of
drugs. Protein was assayed by the Bradford method using
BioRad protein assay reagents (BioRad, Hercules, CA).
Measurement of CDP-diacylglycerol accumulation
Accumulation of CDP-diacylglycerol was measured in
brain slice preparations by taking advantage of the CTP-
phosphatidate transfer reaction as previously described in
detail [75-77]. Briefly, male Sprague-Dawley rats weighing
between 225 and 300 g were rapidly decapitated and the
brains removed and rinsed in calcium-free HBB [75,78].
Brain regions of interest, including the prefrontal cortex,
hippocampus, and striatum, were quickly dissected out
and 350 μm prisms prepared using a McIlwain tissue
chopper [78]. The slices were washed with calcium-free
HBB and pre-incubated for 45 minutes at 37°C. Slice aliq-
uots of approximately 300 μg protein were then incubated
with 1.5 μCi of 5- [3H]cytidine (20 Ci/mmol; American
Radiolabeled Chemicals, St. Louis, MO) in order to gener-
ate an endogenous pool of radiolabeled cytidine triphos-
phate (CTP) for feeding into the CTP:phosphatidate
transfer reaction [75]. Following addition of 5 mM LiCl,
test drugs or buffer were added for a total volume of 250
μl, and incubation continued for 60 or 90 min as indi-
cated. Reactions were terminated by addition of 1.5 ml
chloroform-methanol-1M HCl (100:200:1). Formed lip-
ids were extracted by liquid partitioning in chloroform
followed by centrifugation at 1000 × g for 5 min in order
to separate the liquid phases. Aliquots of the organic
phase were quantitatively transferred into scintillation
vials, dried at room temperature, and redissolved in
Biosafe scintillation cocktail. Radioactivity in this lipid
fraction was determined by liquid scintillation spectrom-
etry; this activity corresponds to [3H]CDP-DG as previ-
ously indicated [63,75,79], and confirmed by us through
thin layer chromatographic analysis of the reaction prod-
ucts (unpublished observations).
Measurement of inositol phospholipid resynthesis
Brain tissues were prepared and incubated as described
above for assaying CDP-DG, except that 1.5 μCi of
[3H]inositol (20 Ci/mmol; American Radiolabeled Chem-
icals, St. Louis, MO) was used instead of [3H]cytidine to
label the slices. Following the labeling incubation, drugs
were added and allowed to act for 60 or 90 min as indi-
cated. Samples were extracted with chloroform-methanol-
1M HCl (100:200:1), partitioned with chloroform into
aqueous and organic phases, and aliquots of the organic
phase dried and assessed for radioactivity that corre-
sponded to the inositol phospholipids. For purposes of
the present study, it was not necessary to attempt to sepa-
rate the multiple phosphorylated or isomeric forms of
these phospholipids. Hence, the data potentially repre-
sent the mix of phosphatidylinositol, phosphatidylinosi-
tol-4-phosphate, and phosphatidylinositol 4,5-
bisphosphate in any of their positional isomeric forms.
Based on the levels of the phospholipids present at the
start of drug treatment, a subsequent decrease is seen as
depletion, whereas an increase in the [3H]inositol-labeled
pool of the phospholipids is considered to represent fur-
ther phospholipid synthesis or resynthesis [76,80].
Measurement of inositol phosphate accumulation
To measure the levels of IPs formed, tissues were treated
exactly as in the foregoing PI synthesis assays, including
the use of [3H]inositol for prelabeling of the PI pool. The
250 μl reactions were terminated by mixing the samples
with 1.5 ml of chloroform – methanol – 1 M HCl
(100:200:1). Following chloroform-mediated partition-
ing of the extracts as described [65], aliquots of the aque-
ous phase were analyzed for the content of [3H]IPs by
Dowex anion exchange chromatography [65,78]. An IP
fraction was collected from the eluate and the solution
converted into a gel by use of Scintisafe Gel (Fisher Scien-
tific, Pittsburgh, PA). The amounts of IP-associated radio-
activity in the samples were then measured by liquid
scintillation spectrometry.
Data analysis
Data from the various experiments were normalized rela-
tive to the respective control or basal measurements, and
then pooled for analysis. Data were tested by an appropri-
ate analysis of variance (ANOVA) using SPSS softwareBMC Neuroscience 2008, 9:12 http://www.biomedcentral.com/1471-2202/9/12
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(SPSS, Chicago, IL, USA). Where warranted, the ANOVAs
were followed by post hoc analyses using the Dunnett test
to compare various treatment means to their respective
controls. Statistical comparisons were considered signifi-
cant at p < 0.05 or better.
Authors' contributions
KRT participated in experimental design, carried out the
majority of the experiments, and drafted the manuscript.
HOUV participated in data collection. ASU conceived of
the study, directed the experiments, and participated in
the data analysis and writing of the manuscript. All
authors read and approved the final manuscript.
Acknowledgements
This research was supported by grant #DA017614 from the US National 
Institutes of Health.
References
1. Waslick BD, Kandel R, Kakouros A: Depression in children and
adolescents: an overview.  In The many faces of depression in chil-
dren and adolescents Edited by: Shaffer D and Waslick BD. Washington
DC, American Psychiatric Publishing, Inc.; 2002:1-29. 
2. Costello EJ, Mustillo S, Erkanli A, Keeler G, Angold A: Prevalence
and development of psychiatric disorders in childhood and
adolescence.  Arch Gen Psychiatry 2003, 60:837-844.
3. Hasin DS, Goodwin RD, Stinson FS, Grant BF: Epidemiology of
major depressive disorder: results from the National Epide-
miologic Survey on Alcoholism and Related Conditions.  Arch
Gen Psychiatry 2005, 62:1097-1106.
4. Ciraulo DA, Tsirulnik-Barts L, Shader RI, Greenblatt DJ: Clinical
pharmacology and therapeutics of antidepressants.  In Phar-
macotherapy of depression Edited by: Ciraulo DA and Shader RI.
Totowa NJ, Humana Press; 2004:33-119. 
5. Taylor C, Fricker AD, Devi LA, Gomes I: Mechanisms of action of
antidepressants: from neurotransmitter systems to signaling
pathways.  Cell Signal 2005, 17:549-557.
6. Feighner JP: Mechanism of action of antidepressant medica-
tions.  J Clin Psychiatry 1999, 60:4-11.
7. Frazer A: Norepinephrine involvement in antidepressant
action.  J Clin Psychiatry 2000, 61:25-30.
8. Gould TD, Manji HK: Signaling networks in the pathophysiol-
ogy and treatment of mood disorders.  J Psychosom Res 2002,
53:687-697.
9. Coyle JT, Duman RS: Finding the intracellular signaling path-
ways affected by mood disorder treatments.  Neuron 2003,
38:157-160.
10. Delgado PL: How antidepressants help depression: mecha-
nisms of action and clinical response.  J Clin Psychiatry 2004,
65:25-30.
11. De Vivo M, Maayani S: Characterization of the 5-
hydroxytryptamine1a receptor-mediated inhibition of for-
skolin-stimulated adenylate cyclase activity in guinea pig and
rat hippocampal membranes.  J Pharmacol Exp Ther 1986,
238:248-253.
12. De Vivo M, Maayani S: Stimulation and inhibition of adenylyl
cyclase by distinct 5-hydroxytryptamine receptors.  Biochem
Pharmacol 1990, 40:1551-1558.
13. Dumuis A, Sebben M, Bockaert J: Pharmacology of 5-hydrox-
ytryptamine-1A receptors which inhibit cAMP production in
hippocampal and cortical neurons in primary culture.  Mol
Pharmacol 1988, 33:178-186.
14. Undie AS, Weinstock J, Sarau HM, Friedman E: Evidence for a dis-
tinct D1-like dopamine receptor that couples to activation of
phosphoinositide metabolism in brain.  J Neurochem 1994,
62:2045-2048.
15. Dwivedi Y, Agrawal AK, Rizavi HS, Pandey GN: Antidepressants
reduce phosphoinositide-specific phospholipase C (PI-PLC)
activity and the mRNA and protein expression of selective
PLC beta 1 isozyme in rat brain.  Neuropharmacology 2002,
43:1269-1279.
16. Fumagalli F, Molteni R, Calabrese F, Frasca A, Racagni G, Riva MA:
Chronic fluoxetine administration inhibits extracellular sig-
nal-regulated kinase 1/2 phosphorylation in rat brain.  J Neu-
rochem 2005, 93:1551-1560.
17. Chen J, Rasenick MM: Chronic antidepressant treatment facili-
tates G protein activation of adenylyl cyclase without alter-
ing G protein content.  J Pharmacol Exp Ther 1995, 275:509-517.
18. Hines LM, Tabakoff B: Platelet adenylyl cyclase activity: a bio-
logical marker for major depression and recent drug use.  Biol
Psychiatry 2005, 58:955-962.
19. Odagaki Y, Garcia-Sevilla JA, Huguelet P, La Harpe R, Koyama T, Gui-
mon J: Cyclic AMP-mediated signaling components are
upregulated in the prefrontal cortex of depressed suicide vic-
tims.  Brain Res 2001, 898:224-231.
20. Shimizu M, Nishida A, Zensho H, Yamawaki S: Chronic antidepres-
sant exposure enhances 5-hydroxytryptamine7 receptor-
mediated cyclic adenosine monophosphate accumulation in
rat frontocortical astrocytes.  J Pharmacol Exp Ther 1996,
279:1551-1558.
21. Qu Y, Chang L, Klaff J, Seemann R, Rapoport SI: Imaging brain
phospholipase A2-mediated signal transduction in response
to acute fluoxetine administration in unanesthetized rats.
Neuropsychopharmacology 2003, 28:1219-1226.
22. Nibuya M, Nestler EJ, Duman RS: Chronic antidepressant admin-
istration increases the expression of cAMP response ele-
ment binding protein (CREB) in rat hippocampus.  J Neurosci
1996, 16:2365-2372.
23. Yamada S, Yamamoto M, Ozawa H, Riederer P, Saito T: Reduced
phosphorylation of cyclic AMP-responsive element binding
protein in the postmortem orbitofrontal cortex of patients
with major depressive disorder.  J Neural Transm 2003,
110:671-680.
24. Fukuda H, Nishida A, Saito H, Shimizu M, Yamawaki S: Imipramine
stimulates phospholipase C activity in rat brain.  Neurochem Int
1994, 25:567-571.
25. Pacheco MA, Stockmeier C, Meltzer HY, Overholser JC, Dilley GE,
Jope RS: Alterations in phosphoinositide signaling and G-pro-
tein levels in depressed suicide brain.  Brain Res 1996, 723:37-45.
26. Butler PD, Barkai AI: Agonist-stimulation of cerebral phosphoi-
nositide turnover following long-term treatment with anti-
depressants.  Adv Exp Med Biol 1987, 221:531-547.
27. Osborne NN: Tricyclic antidepressants, mianserin, and oua-
bain stimulate inositol phosphate formation in vitro in rat
cortical slices.  Neurochem Res 1988, 13:105-111.
28. Sanders-Bush E, Breeding M, Knoth K, Tsutsumi M: Sertraline-
induced desensitization of the serotonin 5HT-2 receptor
transmembrane signaling system.  Psychopharmacology (Berlin)
1989, 99:64-69.
29. Pandey GN, Pandey SC, Davis JM: Effect of desipramine on inosi-
tol phosphate formation and inositol phospholipids in rat
brain and human platelets.  Psychopharmacol Bull 1991,
27:255-261.
30. Pandey SC, Davis JM, Schwertz DW, Pandey GN: Effect of antide-
pressants and neuroleptics on phosphoinositide metabolism
in human platelets.  J Pharmacol Exp Ther 1991, 256:1010-1018.
31. Morishita S, Aoki S, Watanabe S: Different effect of desipramine
on protein kinase C in platelets between bipolar and major
depressive disorders.  Psychiatry Clin Neurosci 1999, 53:11-15.
32. Morishita S, Aoki S: Effects of tricyclic antidepressants on pro-
tein kinase C activity in rabbit and human platelets in vivo.  J
Affect Disord 2002, 70:329-332.
33. Mann CD, Vu TB, Hrdina PD: Protein kinase C in rat brain cor-
tex and hippocampus: effect of repeated administration of
fluoxetine and desipramine.  Br J Pharmacol 1995, 115:595-600.
34. Einat H, Yuan P, Gould TD, Li J, Du J, Zhang L, Manji HK, Chen G:
The role of the extracellular signal-regulated kinase signal-
ing pathway in mood modulation.  J Neurosci 2003,
23:7311-7316.
35. Shimizu M, Nishida A, Hayakawa H, Yamawaki S: Ca2+ release
from inositol 1,4,5-trisphosphate-sensitive Ca2+ store by
antidepressant drugs in cultured neurons of rat frontal cor-
tex.  J Neurochem 1993, 60:595-601.BMC Neuroscience 2008, 9:12 http://www.biomedcentral.com/1471-2202/9/12
Page 17 of 18
(page number not for citation purposes)
36. Cuellar-Quintero JL, Garcia DE, Cruzblanca H: The antidepressant
imipramine inhibits the M-type K+ current in rat sympa-
thetic neurons.  Neuroreport 2001, 12:2195-2198.
37. Coppell AL, Pei Q, Zetterstrom TS: Bi-phasic change in BDNF
gene expression following antidepressant drug treatment.
Neuropharmacology 2003, 44:903-910.
38. Saarelainen T, Hendolin P, Lucas G, Koponen E, Sairanen M, MacDon-
ald E, Agerman K, Haapasalo A, Nawa H, Aloyz R, Ernfors P, Castren
E: Activation of the TrkB neurotrophin receptor is induced
by antidepressant drugs and is required for antidepressant-
induced behavioral effects.  J Neurosci 2003, 23:349-357.
39. Xu H, Steven RJ, Li XM: Dose-related effects of chronic antide-
pressants on neuroprotective proteins BDNF, Bcl-2 and Cu/
Zn-SOD in rat hippocampus.  Neuropsychopharmacology 2003,
28:53-62.
40. Wong ML, Khatri P, Licinio J, Esposito A, Gold PW: Identification
of hypothalamic transcripts upregulated by antidepressants.
Biochem Biophys Res Commun 1996, 229:275-279.
41. Manev R, Uz T, Manev H: Fluoxetine increases the content of
neurotrophic protein S100beta in the rat hippocampus.  Eur
J Pharmacol 2001, 420:R1-R2.
42. Dziedzicka-Wasylewska M, Dlaboga D, Pierzchala-Koziec K, Rogoz Z:
Effect of tianeptine and fluoxetine on the levels of Met-
enkephalin and mRNA encoding proenkephalin in the rat.  J
Physiol Pharmacol 2002, 53:117-125.
43. Duman RS, Nakagawa S, Malberg J: Regulation of adult neurogen-
esis by antidepressant treatment.  Neuropsychopharmacology
2001, 25:836-844.
44. Malberg JE, Eisch AJ, Nestler EJ, Duman RS: Chronic antidepres-
sant treatment increases neurogenesis in adult rat hippoc-
ampus.  J Neurosci 2000, 20:9104-9110.
45. Manev H, Uz T, Smalheiser NR, Manev R: Antidepressants alter
cell proliferation in the adult brain in vivo and in neural cul-
tures in vitro.  Eur J Pharmacol 2001, 411:67-70.
46. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, Weiss-
taub N, Lee J, Duman R, Arancio O, Belzung C, Hen R: Require-
ment of hippocampal neurogenesis for the behavioral effects
of antidepressants.  Science 2003, 301:805-809.
47. Contreras CM, Rodriguez-Landa JF, Gutierrez-Garcia AG, Bernal-
Morales B: The lowest effective dose of fluoxetine in the
forced swim test significantly affects the firing rate of lateral
septal nucleus neurones in the rat.  J Psychopharmacol 2001,
15:231-236.
48. Dong J, Blier P: Modification of norepinephrine and serotonin,
but not dopamine, neuron firing by sustained bupropion
treatment.  Psychopharmacology (Berl) 2001, 155:52-57.
49. Langosch JM, Walden J: Effects of the atypical antidepressant
trimipramine on neuronal excitability and long-term poten-
tiation in guinea pig hippocampal slices.  Prog Neuropsychophar-
macol Biol Psychiatry 2002, 26:299-302.
50. Lesch KP, Manji HK: Signal-transducing G proteins and antide-
pressant drugs: evidence for modulation of alpha subunit
gene expression in rat brain.  Biol Psychiatry 1992, 32:549-579.
51. Drigues N, Poltyrev T, Bejar C, Weinstock M, Youdim MB: cDNA
gene expression profile of rat hippocampus after chronic
treatment with antidepressant drugs.  J Neural Transm 2003,
110:1413-1436.
52. Landgrebe J, Welzl G, Metz T, van Gaalen MM, Ropers H, Wurst W,
Holsboer F: Molecular characterisation of antidepressant
effects in the mouse brain using gene expression profiling.  J
Psychiatr Res 2002, 36:119-129.
53. Palotas M, Palotas A, Puskas LG, Kitajka K, Pakaski M, Janka Z, Molnar
J, Penke B, Kalman J: Gene expression profile analysis of the rat
cortex following treatment with imipramine and citalopram.
Int J Neuropsychopharmacol 2004, 7:401-413.
54. Coupland NJ, Ogilvie CJ, Hegadoren KM, Seres P, Hanstock CC,
Allen PS: Decreased prefrontal Myo-inositol in major depres-
sive disorder.  Biol Psychiatry 2005, 57:1526-1534.
55. Barkai AI, Dunner DL, Gross HA, Mayo P, Fieve RR: Reduced myo-
inositol levels in cerebrospinal fluid from patients with affec-
tive disorder.  Biol Psychiatry 1978, 13:65-72.
56. Einat H, Karbovski H, Korik J, Tsalah D, Belmaker RH: Inositol
reduces depressive-like behaviors in two different animal
models of depression.  Psychopharmacology (Berl) 1999,
144:158-162.
57. Einat H, Clenet F, Shaldubina A, Belmaker RH, Bourin M: The anti-
depressant activity of inositol in the forced swim test
involves 5-HT(2) receptors.  Behav Brain Res 2001, 118:77-83.
58. Levine J: Controlled trials of inositol in psychiatry.  Eur Neu-
ropsychopharmacol 1997, 7:147-155.
59. Manji HK, Chen G: Post-receptor signaling pathways in the
pathophysiology and treatment of mood disorders.  Curr Psy-
chiatry Rep 2000, 2:479-489.
60. Shelton RC: Intracellular mechanisms of antidepressant drug
action.  Harv Rev Psychiatry 2000, 8:161-174.
61. Nishizuka Y: Intracellular signaling by hydrolysis of phospholi-
pids and activation of protein kinase C.  Science 1992,
258:607-614.
62. Sarri E, Picatoste F, Claro E: Neurotransmitter-specific profiles
of inositol phosphates in rat brain cortex: relation to the
mode of receptor activation of phosphoinositide phospholi-
pase C1.  The Journal of Pharmacology and Experimental Therapeutics
1995, 272:77-84.
63. Claro E, Fain JN, Picatoste F: Noradrenaline stimulation unbal-
ances the phosphoinositide cycle in rat cerebral cortical
slices.  J Neurochem 1993, 60:2078-2086.
64. Tyeryar KR, Undie AS: Diverse antidepressants modulate one
or more components of phosphoinositide signaling cascades
in depression-relevant brain regions.  Soc Neurosci Abstr 2002,
27:306-306.
65. Undie AS, Friedman E: Stimulation of a dopamine D1 receptor
enhances inositol phosphates formation in rat brain.  J Phar-
macol Exp Ther 1990, 253:987-992.
66. Pandey GN, Dwivedi Y, Kumari R, Janicak PG: Protein kinase C in
platelets of depressed patients.  Biol Psychiatry 1998, 44:909-911.
67. Lucki I, Singh A, Kreiss DS: Antidepressant-like behavioral
effects of serotonin receptor agonists.  Neurosci Biobehav Rev
1994, 18:85-95.
68. Cryan JF, Lucki I: Antidepressant-like behavioral effects medi-
ated by 5-Hydroxytryptamine(2C) receptors.  J Pharmacol Exp
Ther 2000, 295:1120-1126.
69. D'Aquila PS, Collu M, Pani L, Gessa GL, Serra G: Antidepressant-
like effect of selective dopamine D1 receptor agonists in the
behavioural despair animal model of depression.  Eur J Pharma-
col 1994, 262:107-111.
70. Tyeryar KR, Undie AS: Tandem regulation of phosphoinositide
signaling and acute behavioral effects induced by antidepres-
sant agents in rats.  Psychopharmacology (Berl) 2007, 193:271-282.
71. Downes CP, Carter AN: Phosphoinositide 3-kinase: a new
effector in signal transduction?  Cell Signal 1991, 3:501-513.
72. Daw MI, Bortolotto ZA, Saulle E, Zaman S, Collingridge GL, Isaac JT:
Phosphatidylinositol 3 kinase regulates synapse specificity of
hippocampal long-term depression.  Nat Neurosci 2002,
5:835-836.
73. Edstrom A, Ekstrom PA: Role of phosphatidylinositol 3-kinase in
neuronal survival and axonal outgrowth of adult mouse dor-
sal root ganglia explants.  J Neurosci Res 2003, 74:726-735.
74. Hsiung SC, Adlersberg M, Arango V, Mann JJ, Tamir H, Liu KP: Atten-
uated 5-HT1A receptor signaling in brains of suicide victims:
involvement of adenylyl cyclase, phosphatidylinositol 3-
kinase, Akt and mitogen-activated protein kinase.  J Neuro-
chem 2003, 87:182-194.
75. Undie AS: Relationship between dopamine agonist stimula-
tion of inositol phosphate formation and cytidine diphos-
phate-diacylglycerol accumulation in brain slices.  Brain Res
1999, 816:286-294.
76. Panchalingam S, Undie AS: SKF83959 exhibits biochemical ago-
nism by stimulating phosphoinositide hydrolysis and
[35S]GTPgS binding in rat and monkey brain.  Neuropharma-
cology 2001, 40:826-837.
77. Godfrey PP: Potentiation by lithium of CMP-phosphatidate
formation in carbachol-stimulated rat cerebral-cortical
slices and its reversal by myo-inositol.  Biochem J 1989,
258:621-624.
78. Undie AS, Friedman E: Selective dopaminergic mechanism of
dopamine and SKF38393 stimulation of inositol phosphate
formation in rat brain.  Eur J Pharmacol 1992, 226:297-302.
79. Stubbs EB Jr., Agranoff BW: Lithium enhances muscarinic recep-
tor-stimulated CDP-diacylglycerol formation in inositol-
depleted SK-N-SH neuroblastoma cells.  J Neurochem 1993,
60:1292-1299.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Neuroscience 2008, 9:12 http://www.biomedcentral.com/1471-2202/9/12
Page 18 of 18
(page number not for citation purposes)
80. Billah MM, Michell RH: Stimulation of the breakdown and
resynthesis of phosphatidylinositol in rat hepatocytes by
angiotensin, vasopressin and adrenaline.  Biochem Soc Trans
1978, 6:1033-1035.